UA98772C2 - Производные циклопропиламина как модуляторы н3-гистаминового рецептора - Google Patents

Производные циклопропиламина как модуляторы н3-гистаминового рецептора

Info

Publication number
UA98772C2
UA98772C2 UAA200900472A UAA200900472A UA98772C2 UA 98772 C2 UA98772 C2 UA 98772C2 UA A200900472 A UAA200900472 A UA A200900472A UA A200900472 A UAA200900472 A UA A200900472A UA 98772 C2 UA98772 C2 UA 98772C2
Authority
UA
Ukraine
Prior art keywords
histamin
receptor modulators
amine derivatives
cyclopropyl amine
compounds
Prior art date
Application number
UAA200900472A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хуацин Лю
Лоренс А. Блек
Юссеф Д. Беннани
Марлон Д. КАУЭРТ
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA98772C2 publication Critical patent/UA98772C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы (I)(I),полезны при лечении состояний или нарушений, которые предотвращают или которые облегчают с помощью лигандов Н-гистаминовых рецепторов.Также раскрыты фармацевтические композиции, которые содержат лиганды Н-гистаминовых рецепторов, применение таких соединений и композиций и способ получения соединений, которые входят в область, которая определяется формулой (I).
UAA200900472A 2006-06-23 2007-06-22 Производные циклопропиламина как модуляторы н3-гистаминового рецептора UA98772C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81593406P 2006-06-23 2006-06-23

Publications (1)

Publication Number Publication Date
UA98772C2 true UA98772C2 (ru) 2012-06-25

Family

ID=38670977

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200900472A UA98772C2 (ru) 2006-06-23 2007-06-22 Производные циклопропиламина как модуляторы н3-гистаминового рецептора

Country Status (22)

Country Link
US (1) US8829041B2 (ru)
EP (1) EP2049472B1 (ru)
JP (1) JP5203360B2 (ru)
KR (1) KR20090024811A (ru)
CN (2) CN103382174A (ru)
AU (1) AU2007260836B2 (ru)
BR (1) BRPI0712823A2 (ru)
CA (1) CA2655604C (ru)
CR (1) CR10540A (ru)
DO (1) DOP2011000283A (ru)
EC (1) ECSP099046A (ru)
ES (1) ES2533009T3 (ru)
IL (1) IL196094A0 (ru)
MX (1) MX2008016343A (ru)
NO (1) NO20090282L (ru)
NZ (2) NZ611323A (ru)
RU (1) RU2449989C2 (ru)
SG (1) SG173312A1 (ru)
TW (1) TW200808773A (ru)
UA (1) UA98772C2 (ru)
UY (1) UY31527A1 (ru)
WO (1) WO2007150010A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4981794B2 (ja) * 2005-06-03 2012-07-25 アボット・ラボラトリーズ シクロブチルアミン誘導体
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
PT2195293E (pt) 2007-08-22 2014-01-21 Astrazeneca Ab Derivados da ciclopropilamida
AU2013216616B2 (en) * 2007-12-14 2016-04-21 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
AU2011218490B9 (en) * 2010-02-18 2014-12-18 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
RU2012136148A (ru) 2010-02-18 2014-03-27 Астразенека Аб Новая кристаллическая форма производного циклопропилбензамида
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128365C (ru) 1963-11-05
FR2508033A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses
EP0188887B1 (en) 1985-01-17 1991-05-02 Imperial Chemical Industries Plc Tertiary amine compounds
GB8615313D0 (en) 1986-06-23 1986-07-30 Ici Plc Chemical process
GB8621790D0 (en) 1986-09-10 1986-10-15 Ici Plc Tertiary amine compounds
GB2210364A (en) 1987-09-29 1989-06-07 Ici Plc Cyclopropane ring-containing tertiary amine derivatives
US5086054A (en) 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9401436D0 (en) 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
FR2716192B1 (fr) 1994-02-17 1996-04-12 Rhone Poulenc Agrochimie Dérivés de 2-imidazoline-5-ones fongicides.
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
DE19821002A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2000047358A (ja) 1998-07-28 2000-02-18 Fuji Photo Film Co Ltd 感光材料処理装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3033100A (en) 1999-01-18 2000-08-01 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
WO2000064884A1 (en) 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
US6620839B2 (en) 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
US6515013B2 (en) 2000-07-13 2003-02-04 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
WO2002013821A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
US6996472B2 (en) 2000-10-10 2006-02-07 The United States Of America As Represented By The Department Of Health And Human Services Drift compensation method for fingerprint spectra
AU2002219920A1 (en) 2000-11-28 2002-06-11 Sunesis Pharmaceuticals, Inc. Salicylate analogs as interleukin-4 antagonists
JP2002236340A (ja) 2001-02-09 2002-08-23 Konica Corp ハロゲン化銀写真感光材料の自動現像機による処理方法
CA2440238C (en) 2001-03-16 2011-09-13 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE10153345A1 (de) 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
DE10153347A1 (de) 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinolin-2-on-Verbindungen
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CN1628109A (zh) 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
EP1505966A4 (en) * 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
ATE356127T1 (de) 2002-06-06 2007-03-15 Novo Nordisk As Substituierte hexahydropyrrolo(1,2-a)pyrazine, octahydropyrido(1,2-a)pyrazine und decahydropyrazino(1,2-a)azepine
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7381719B2 (en) 2002-09-19 2008-06-03 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
SI1558595T1 (sl) 2002-10-23 2010-03-31 Janssen Pharmaceutica Nv Piperazinilni in diazapanilni benzamidi in benztioamidi
AU2003275838A1 (en) 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
CA2505427C (en) 2002-11-12 2012-04-03 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
WO2004046110A1 (ja) 2002-11-15 2004-06-03 Yamanouchi Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗剤
MXPA05006567A (es) 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
JP4458333B2 (ja) 2003-02-13 2010-04-28 キヤノン株式会社 露光装置、およびデバイスの製造方法
AR044045A1 (es) 2003-04-23 2005-08-24 Glaxo Group Ltd Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
KR20100106630A (ko) 2003-05-05 2010-10-01 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2004099199A1 (en) 2003-05-06 2004-11-18 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US7094790B2 (en) 2003-05-07 2006-08-22 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
JP2007528860A (ja) 2003-07-28 2007-10-18 財団法人大阪産業振興機構 血糖降下用組成物
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
GB0319211D0 (en) 2003-08-15 2003-09-17 Koninkl Philips Electronics Nv Antenna arrangement and a module and a radio communications apparatus having such an arrangement
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
JP4617837B2 (ja) 2003-11-21 2011-01-26 チッソ株式会社 フッ化アルキレンを有する重合性を有する液晶性化合物およびその重合体
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
EP1718309A2 (en) 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
WO2005080361A1 (en) * 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
EP1717230B1 (en) 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
GB0405628D0 (en) 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
JP2005281223A (ja) 2004-03-30 2005-10-13 Chisso Corp １，２−シクロヘキシレン環を有する光学活性化合物、液晶組成物、液晶表示素子、成形体
US7345034B2 (en) 2004-04-07 2008-03-18 Abbott Laboratories Azacyclosteroid histamine-3 receptor ligands
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
EA011161B1 (ru) * 2004-05-07 2009-02-27 Уорнер-Ламберт Компани Ллс 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве h-лигандов
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
EP1756094A1 (en) 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
EP1773345B1 (en) 2004-06-30 2013-12-11 Athersys, Inc. Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US20060074103A1 (en) * 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
PT1802307E (pt) 2004-10-15 2008-06-06 Glaxo Group Ltd Derivados de pirrolidina como ligandos de receptores de histamina
US20090306052A1 (en) 2004-12-07 2009-12-10 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
US7560453B2 (en) 2005-01-07 2009-07-14 Glaxo Group Limited 6-(2, 3, 4, 5-tetrahydro-1H-benzo [D] azepin-7-yloxy) -nicotamide derivatives as radio labelled ligands
US7790731B2 (en) 2005-02-14 2010-09-07 Banyu Pharmaceutical Co. Ltd. Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone
WO2006090142A1 (en) 2005-02-24 2006-08-31 Glaxo Group Limited l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST
JP2008533117A (ja) 2005-03-14 2008-08-21 グラクソ グループ リミテッド ヒスタミンｈ３受容体に対して親和性を有する縮合チアゾール誘導体
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1707204A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
JP2008540618A (ja) 2005-05-18 2008-11-20 ブルスター，ジークフリート ソマトスタチン受容体サブタイプ１及び／又は４に選択的なペプチド模倣薬
JP4981794B2 (ja) 2005-06-03 2012-07-25 アボット・ラボラトリーズ シクロブチルアミン誘導体
EP1900733A4 (en) 2005-06-07 2009-12-30 Banyu Pharma Co Ltd PROCESS FOR THE PRODUCTION OF 4 (3H) -QUINAZOLINONE DERIVATIVE
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
JP4240146B2 (ja) 2005-07-05 2009-03-18 萬有製薬株式会社 ４（３ｈ）−キナゾリノン誘導体の製造方法
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
WO2007025144A1 (en) 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EA014370B1 (ru) 2005-09-16 2010-10-29 Янссен Фармацевтика Н.В. Циклопропиламины в качестве модуляторов рецептора гистамина н
JP4860700B2 (ja) 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン
US7576110B2 (en) 2005-09-22 2009-08-18 Abbott Laboratories Benzothiazole cyclobutyl amine derivatives
US7943605B2 (en) 2005-10-27 2011-05-17 Ucb Pharma S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
EP1945639A1 (en) 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
EP1962855B1 (en) 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
WO2007091106A2 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
DK2402317T3 (da) 2006-03-31 2013-10-07 Novartis Ag DGAT-inhibitor
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
PL2069312T3 (pl) 2006-07-25 2013-03-29 Cephalon Inc Pochodne pirydazynonu
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064310A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Mixed opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
EP2117526B1 (en) 2006-11-29 2013-04-03 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
SI2124933T1 (sl) 2007-01-22 2012-12-31 Pfizer Products Inc. Tosilatna sol terapevtske spojine in farmacevtski sestavi tega
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
CL2008000596A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
RU2470011C2 (ru) 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
EP2167096A4 (en) 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP2010531874A (ja) 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
CA2694253A1 (en) 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
PT2195293E (pt) 2007-08-22 2014-01-21 Astrazeneca Ab Derivados da ciclopropilamida
PE20091199A1 (es) 2007-09-06 2009-09-12 Glaxo Group Ltd Derivado de piperazina que tiene afinidad por el receptor de histamina h3
US20100317679A1 (en) 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
PE20091682A1 (es) 2007-12-20 2009-12-04 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
EP2238144A1 (en) 2008-01-24 2010-10-13 UCB Pharma, S.A. Compounds comprising a cyclobutoxy group
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
WO2009115874A2 (en) 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
WO2009124553A2 (en) 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
JP2011524344A (ja) 2008-06-06 2011-09-01 ユセベ ファルマ ソシエテ アノニム シクロブトキシ基を含む化合物
CA2727242A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
US8268846B2 (en) 2008-07-11 2012-09-18 Abbott Laboratories Amino heterocyclic linked pyrimidine derivatives
JP2011528341A (ja) 2008-07-18 2011-11-17 武田薬品工業株式会社 ベンズアゼピン誘導体及びそれらのヒスタミンｈ３拮抗薬としての使用
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
EP2328930B1 (en) 2008-08-20 2014-12-24 Probiodrug AG Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011083315A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Compounds and their use
WO2011083316A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
AR079851A1 (es) 2010-01-08 2012-02-22 Takeda Pharmaceutical Derivados de benzazepina para tratamiento de desordenes en el sistema nervioso central
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives

Also Published As

Publication number Publication date
UY31527A1 (es) 2009-08-03
NO20090282L (no) 2009-03-19
CR10540A (es) 2009-02-05
RU2009102048A (ru) 2010-07-27
WO2007150010A3 (en) 2008-05-02
JP5203360B2 (ja) 2013-06-05
EP2049472B1 (en) 2015-01-21
MX2008016343A (es) 2009-01-19
JP2009541350A (ja) 2009-11-26
RU2449989C2 (ru) 2012-05-10
CN101472887A (zh) 2009-07-01
AU2007260836A1 (en) 2007-12-27
CN103382174A (zh) 2013-11-06
ES2533009T3 (es) 2015-04-06
SG173312A1 (en) 2011-08-29
WO2007150010A2 (en) 2007-12-27
CA2655604A1 (en) 2007-12-27
KR20090024811A (ko) 2009-03-09
US20080021081A1 (en) 2008-01-24
US8829041B2 (en) 2014-09-09
EP2049472A2 (en) 2009-04-22
ECSP099046A (es) 2009-02-27
CA2655604C (en) 2016-08-09
NZ597498A (en) 2013-06-28
IL196094A0 (en) 2009-09-01
BRPI0712823A2 (pt) 2012-07-24
NZ611323A (en) 2014-10-31
TW200808773A (en) 2008-02-16
DOP2011000283A (es) 2011-10-31
AU2007260836B2 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
WO2006132914A3 (en) Cyclobutyl amine derivatives
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
MY150990A (en) Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
MX2010006535A (es) Derivados de ciclopropil amina.
MX2007006374A (es) Derivados del 5-hidroxi-benzotiazol que tienen actividad agonista del adrenoreceptor-beta-2.
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
MX2007007720A (es) Derivados de pirrolidinio como receptores m3 muscarinicos.
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MXPA05011739A (es) Derivados de quinuclidina que se enlazan con los receptores muscarinicos m3.
HK1109767A1 (en) Quaternary ammonium salts as m3 antagonists
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
WO2010151815A3 (en) 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
IN2014DN04587A (ru)
HK1128462A1 (en) Novel method for preparation of ammonium salts of esomeprazole
TNSN05279A1 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
UA94242C2 (ru) Производные бензотиазолциклобутиламина и их применение как лигандов рецепторов гистамина-3
MX2009005388A (es) Derivados de acetileno como inhibidores de estearoil coa desaturasa.